Loading organizations...
§ Private Profile · Zürich, Switzerland
Nanomaterial integration equipment developer, providing high-precision robotic and AI systems for next-generation semiconductor and quantum computing.
Based in Zurich, Switzerland, Chiral develops high-precision robotic and AI-enabled equipment designed to integrate nanomaterials like carbon nanotubes and graphene into next-generation semiconductor and quantum computing chips. The company provides scalable, contamination-free manufacturing systems that replace conventional chemical processes for electronics manufacturers and early pilot customers operating in the global chipmaking industry. To support its ongoing commercialization efforts, Chiral has secured approximately $15.8 million in total venture financing, highlighted by a $12 million seed round in February 2026 and a $3.8 million pre-seed round in 2023. The enterprise is backed by a syndicate of prominent venture capital firms and institutional investors, specifically including Crane Venture Partners, Quantonation, HCVC, and Founderful. Operating as an official commercial spin-off from the research institution ETH Zurich, Chiral was founded in 2023 by Seoho Jung, Natanael Lanz, and Andre Butzerin.
Chiral has raised $16.2M across 3 funding rounds.
Chiral has raised $16.2M in total across 3 funding rounds.
Daicel Chiral Technologies (formerly Chiral Technologies, Inc.) is a leading provider of chiral chromatography solutions, specializing in the separation of optical isomers (enantiomers) for the pharmaceutical, agrochemical, and life science industries.[1][2][5] As a wholly-owned subsidiary of Japan's Daicel Chemical Industries, Ltd., the company offers the world's broadest portfolio of chiral stationary phases (CSPs), high-performance liquid chromatography (HPLC) and supercritical fluid chromatography (SFC) columns for analytical, semi-preparative, and preparative scales, plus custom separation services from method development to multi-kilogram purification.[1][2][3] It solves critical challenges in drug discovery, process development, and manufacturing single-enantiomer products, delivering durable, high-performance tools that reduce costs and enable previously impossible separations.[1][2]
The company maintains strong growth momentum through continuous innovation, such as immobilized CSPs (e.g., CHIRALPAK® IA™, IB™, IC™) for low-solubility compounds and 3-µm particle columns for high-throughput screening, while serving global markets via subsidiaries in North America (West Chester, PA) and Europe (Illkirch, France).[2][3][5]
Daicel Chiral Technologies traces its roots to Daicel Chemical Industries, Ltd., which pioneered the chiral chromatography industry nearly 40 years ago by developing polysaccharide-based CSPs that revolutionized enantiomer separation.[1][2] Established as Chiral Technologies, Inc. in West Chester, Pennsylvania, it became a wholly-owned subsidiary of Daicel, leveraging the parent company's fine chemicals expertise to expand into a global leader.[2][3][4] Key milestones include launching industry-standard columns, innovative immobilized phases for enhanced robustness, and bulk CSPs for process-scale use, with early focus on pharmaceutical needs driving rapid adoption in drug development.[1][2] This evolution from niche innovator to comprehensive service provider was propelled by unmatched technical expertise, enabling custom solutions for complex racemic resolutions.[1][5]
Daicel Chiral Technologies rides the wave of precision medicine and biologics, where enantiomer purity is essential for drug safety, efficacy, and regulatory approval amid rising demand for single-isomer therapeutics.[2][5] Timing aligns with SFC adoption for greener, faster separations over traditional HPLC, plus outsourcing trends in late-stage pharma development to cut timelines and costs.[1][2] Market forces like complex molecule pipelines and agrochemical innovation favor its expertise, influencing the ecosystem by enabling faster drug discovery—its columns and services underpin commercial single-enantiomer production worldwide.[1][3]
Next steps likely include expanding SFC capabilities, AI-driven method optimization, and larger-scale services to support gene therapy and novel modalities demanding ultra-pure isomers.[1][5] Trends like sustainable chromatography and personalized medicine will propel growth, potentially amplifying its influence through partnerships with CROs and big pharma. As the trusted chiral separation backbone, it remains pivotal for tomorrow's breakthroughs, echoing its legacy of turning separation impossibilities into industry standards.[1][2]
Chiral has raised $16.2M in total across 3 funding rounds.
Chiral's investors include Crane Venture Partners, HCVC, Innosuisse, Quantonation, Wingman Ventures, Founderful, Astanor Ventures, Earlybird Venture Capital, First Round Capital, General Catalyst, Hardware Club, Night Capital.
Chiral has raised $16.2M across 3 funding rounds. Most recently, it raised $12.0M Seed in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 6, 2026 | $12M Seed | Crane Venture Partners | HCVC, Innosuisse, Quantonation, Wingman Ventures, Founderful, Hardware Club | Announced |
| Feb 1, 2024 | $4M Seed | — | Astanor Ventures, Earlybird Venture Capital, First Round Capital, Founderful, General Catalyst, Hardware Club, Night Capital, ETH Zurich, Venture Kick | Announced |
| Nov 6, 2023 | $170K Grant | Venture Kick | — | Announced |